"Active Component" will receive equipment for 120 million rubles

13 April 2016

Gazprombank Leasing Standard LLC and St.Petersburg manufacturer of pharmaceuticals “Acticomp” signed an agreement under which the plant acquires new equipment in the amount of more than 120 million rubles under the first tranche of equipment supplies for the new line of production facilities. As DP reported earlier, “Acticomp” invests 300 million rubles in expanding the capacity of its plant by 50%, up to 40 tons of substances per year. A number of leasing contracts have already been signed, the equipment deliveries are expected to begin in May this year. Thanks to the program of the Ministry of industry and trade, “Acticomp” expects to receive assistance from the state in the form of return of about 50% of the leasing equipment cost.

The new process and laboratory equipment is designed for the development of synthesis technology and subsequent production of pharmaceutical substances within the framework of the import substitution project. CJSC “Acticomp” is one of the few domestic manufacturers of active pharmaceutical substances in the Russian market. The company equally belongs to Alexander Semenov, ex-general director of First Aid pharmacies chain, and Zievuddin Khojaev, a former member of VERTEX.

According to official accounting data, by the end of 2015 the company received revenue in the amount of 595.8 million rubles, which is 90.3% more than that it was in 2014. Net profit for the same period increased by 24.5% to 104.1 million rubles. According to preliminary results for the first quarter of 2016, the revenue amounted to 199.7 million rubles, which is 78% higher than the same period last year, net profit increased by 225% to 44 million rubles.

According to RNC Pharma, “Acticomp” occupies about 8% of the Russian market of pharmaceutical substances production, which in the first 9 months of 2015 amounted to about 2.8 billion rubles (an increase of 7%). The leading manufacturers of pharmaceutical substances in the country are Pharmapark with a share of 27% and Polysynthesis with 16%.